How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?

Joshua J. Neumiller, Rita R. Kalyani

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1667-1669
Number of pages3
JournalClinical journal of the American Society of Nephrology : CJASN
Volume14
Issue number11
DOIs
StatePublished - Nov 7 2019

Fingerprint

Sodium-Glucose Transporter 2
Chronic Renal Insufficiency
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Chronic Kidney Failure
Cardiovascular Diseases
Canagliflozin

Keywords

  • Canagliflozin
  • cardiovascular disease
  • cardiovascular outcomes
  • chronic kidney disease
  • chronic renal insufficiency
  • diabetes
  • end stage kidney disease
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2
  • type 2 diabetes

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD? / Neumiller, Joshua J.; Kalyani, Rita R.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 14, No. 11, 07.11.2019, p. 1667-1669.

Research output: Contribution to journalArticle

@article{012d3ee55a6e4e4c926a7ccb39b45fd1,
title = "How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?",
keywords = "Canagliflozin, cardiovascular disease, cardiovascular outcomes, chronic kidney disease, chronic renal insufficiency, diabetes, end stage kidney disease, Hypoglycemic Agents, Sodium-Glucose Transporter 2, type 2 diabetes",
author = "Neumiller, {Joshua J.} and Kalyani, {Rita R.}",
year = "2019",
month = "11",
day = "7",
doi = "10.2215/CJN.05340419",
language = "English (US)",
volume = "14",
pages = "1667--1669",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?

AU - Neumiller, Joshua J.

AU - Kalyani, Rita R.

PY - 2019/11/7

Y1 - 2019/11/7

KW - Canagliflozin

KW - cardiovascular disease

KW - cardiovascular outcomes

KW - chronic kidney disease

KW - chronic renal insufficiency

KW - diabetes

KW - end stage kidney disease

KW - Hypoglycemic Agents

KW - Sodium-Glucose Transporter 2

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85074676353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074676353&partnerID=8YFLogxK

U2 - 10.2215/CJN.05340419

DO - 10.2215/CJN.05340419

M3 - Article

C2 - 31575617

AN - SCOPUS:85074676353

VL - 14

SP - 1667

EP - 1669

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 11

ER -